<DOC>
	<DOCNO>NCT02288520</DOCNO>
	<brief_summary>This longitudinal , observational , prospective , multicentre study conduct metropolitan France , among representative sample office-based mixed practice rheumatology doctor . The aim study describe real life , therapy strategy face patient treat methotrexate monotherapy consult rheumatoid arthritis impact progression disease 6 month .</brief_summary>
	<brief_title>Therapeutic Strategy Patients Treated With Methotrexate Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Adult patient , ambulatory , see rheumatology consultation . With confirmed diagnosis RA ( ACR 1987 ACR/EULAR 2010 criterion ) receive diseasemodifying treatment methotrexate monotherapy . With clinical , functional , structural and/or therapeutic disease progression , rheumatologist intend change therapeutic treatment RA . Informed computer process medical data right access correction . Patient treat methotrexate RA . Already treated biotherapy receive synthetic DMARDs ( diseasemodifying antirheumatic drug ) combination methotrexate . Participating clinical trial rheumatology .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Methotrexate</keyword>
	<keyword>Therapeutic strategy</keyword>
</DOC>